FB 04 - Universitätsmedizin
Johannes Gutenberg-Universität Mainz
- 06131/17-9704 oder 9799 (Sekretariat)
- 06131/17-9669
Graf, Christiana; Dietz, Julia; Muellhaupt, Beat et al.
REAL-LIFE EFFECTIVENESS OF VOXILAPREVIR/VELPATASVIR/SOFOSBUVIR IN HEPATITIS C PATIENTS PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRAL AGENTS (DAA)HEPATOLOGY. Bd. 76. 2022 S. S48-S49
Antony, James W.; Ngo, Hong-Viet V.; Bergmann, Til Ole et al.
Real-time, closed-loop, or open-loop stimulation? Navigating a terminological jungleJOURNAL OF SLEEP RESEARCH. Bd. 31. H. 6. 2022
Welland, Sabrina; Leyh, Catherine; Finkelmeier, Fabian et al.
Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter StudyLIVER CANCER. Bd. 11. H. 3. 2022 S. 219-232
Stoelzl, Dora; Sander, Nicole; Heratizadeh, Annice et al.
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registryBRITISH JOURNAL OF DERMATOLOGY. Bd. 187. H. 6. 2022 S. 1022-1024
Lueftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 16. 2022
Luftner, Diana; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA studyCANCER RESEARCH. Bd. 82. H. 4. 2022
Lazarus, Jeffrey V.; Castera, Laurent; Mark, Henry et al.
REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICEHEPATOLOGY. Bd. 76. 2022 S. S818-S820
Hess, Georg; Dreyling, Martin; Oberic, Lucie et al.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyBRITISH JOURNAL OF HAEMATOLOGY. 2022
Wolfram, Christian; Pfeiffer, Norbert; Hudde, Tobias et al.
Real-world outcomes of anti-VEGF therapy: psychological, social and behavioral factors measured by the ALBATROS data collection instrument BPZ-9INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. Bd. 63. H. 7. 2022
Schumann, Katharina; Mauch, Cornelia; Klespe, Kai-Christian et al.
Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022